Corrigendum to "TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer" [Int. Immunopharmacol. 168 (2026) 115798].
APA
Zhang Y, Wang Q, et al. (2026). Corrigendum to "TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer" [Int. Immunopharmacol. 168 (2026) 115798].. International immunopharmacology, 168(Pt 1), 115850. https://doi.org/10.1016/j.intimp.2025.115850
MLA
Zhang Y, et al.. "Corrigendum to "TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer" [Int. Immunopharmacol. 168 (2026) 115798].." International immunopharmacology, vol. 168, no. Pt 1, 2026, pp. 115850.
PMID
41242935
같은 제1저자의 인용 많은 논문 (5)
- Comment on: "Interpretable machine learning model for predicting early recurrence of pancreatic cancer: integrating intratumoral and peritumoral radiomics with body composition".
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Impact of contrast-enhanced computed tomography surveillance frequency on survival outcomes in patients with stage I-III colorectal cancer: A propensity score-matched retrospective cohort study.
- Dietary restriction genes as modulators of breast cancer risk through metabolic pathways.
- Transcriptomic landscapes underlying response and resistance to HDAC inhibitor chidamide in triple-negative breast cancer.